110 established journals publish at least 20 % of their articles in Cancer Research. 64 of them are fully open access. Where open-access journals charge a fee, the median is 2 650 USD. Highest recent citation rates: Molecular Cancer, Biomarker Research, Journal of Experimental & Clinical Cancer Research.
110 journals
Most relevant first: how much of a journal's work is in Cancer Research, how many articles it publishes and how often they are cited. Click a column to sort.
| Non-coding RNA ResearchElsevier BV | 56 % | 76 | 7.88 | 43 | 1 100 USD |
| Molecular CancerBioMed Central | 31 % | 245 | 29.52 | 284 | 5 090 USD |
| Cancer Cell InternationalBioMed Central | 38 % | 481 | 6.46 | 115 | 3 190 USD |
| Journal of Experimental & Clinical Cancer ResearchBioMed Central | 31 % | 362 | 12.92 | 180 | 4 190 USD |
| Cancer LettersElsevier BV | 29 % | 488 | 10.61 | 265 | Subscription; open access option 4 960 USD |
| Molecular Medicine ReportsSpandidos Publishing | 34 % | 393 | 5.55 | 113 | Subscription |
| Non-Coding RNAMultidisciplinary Digital Publishing Institute | 47 % | 77 | 4.42 | 54 | 2 172 USD |
| Cell Death and DiseaseSpringer Nature | 22 % | 1 011 | 9.56 | 232 | 4 990 USD |
| npj Breast CancerNature Portfolio | 34 % | 133 | 6.17 | 77 | 3 790 USD |
| International Journal of Biological SciencesIvyspring International Publisher | 24 % | 371 | 10.56 | 164 | 1 337 USD |
| Journal of Translational MedicineBioMed Central | 21 % | 969 | 8.33 | 189 | 3 890 USD |
| BioengineeredTaylor & Francis | 46 % | 462 | 1.32 | 86 | 2 864 USD |
| Cell Death DiscoverySpringer Nature | 22 % | 502 | 11.32 | 108 | 2 690 USD |
| Cancer & MetabolismBioMed Central | 44 % | 36 | 5.63 | 67 | 3 190 USD |
| Experimental and Therapeutic MedicineSpandidos Publishing | 26 % | 684 | 3.93 | 90 | Open access, fee unknown |
| Molecular OncologyElsevier BV | 33 % | 237 | 3.44 | 145 | 4 300 USD |
| Breast Cancer Research and TreatmentSpringer Science+Business Media | 29 % | 369 | 3.53 | 220 | Subscription; open access option 4 190 USD |
| Clinical and Translational MedicineSpringer Science+Business Media | 23 % | 429 | 6.84 | 103 | 3 470 USD |
| Translational OncologyElsevier BV | 27 % | 321 | 4.28 | 95 | 3 390 USD |
| Journal of CancerIvyspring International Publisher | 26 % | 426 | 4.48 | 110 | 1 337 USD |
| Journal of Cellular and Molecular MedicineWiley | 24 % | 694 | 4.59 | 186 | 5 210 USD |
| AgingImpact Journals LLC | 22 % | 805 | 4.85 | 162 | Subscription |
| The Journal of Liquid BiopsyElsevier BV | 39 % | 81 | 3.15 | 18 | 2 080 USD |
| Cancer BiomarkersIOS Press | 38 % | 102 | 2.79 | 66 | Subscription |
| MicroRNABentham Science Publishers | 61 % | 35 | 1.58 | 34 | Subscription |
| Pathology - Research and PracticeElsevier BV | 23 % | 508 | 4.72 | 102 | Subscription; open access option 2 780 USD |
| Oncology Research Featuring Preclinical and Clinical Cancer TherapeuticsCognizant Communication Corporation | 36 % | 135 | 2.60 | 67 | Subscription |
| Frontiers in OncologyFrontiers Media | 20 % | 5 383 | 2.70 | 206 | 3 801 USD |
| Biomarker ResearchBioMed Central | 21 % | 124 | 15.02 | 90 | 3 890 USD |
| npj Precision OncologyNature Portfolio | 22 % | 216 | 8.98 | 81 | 4 090 USD |
| Bioscience ReportsPortland Press | 32 % | 224 | 2.61 | 128 | 1 960 USD |
| Mutation Research/Genetic Toxicology and Environmental MutagenesisElsevier BV | 40 % | 72 | 2.59 | 146 | Subscription; open access option 3 350 USD |
| Oncology LettersSpandidos Publishing | 28 % | 603 | 2.19 | 105 | Open access, fee unknown |
| OncoTargets and TherapyDove Medical Press | 33 % | 223 | 2.20 | 111 | 2 836 USD |
| The BreastElsevier BV | 28 % | 462 | 2.30 | 128 | 3 200 USD |
| International Journal of Molecular MedicineSpandidos Publishing | 22 % | 177 | 9.15 | 130 | Subscription |
| Breast Cancer ResearchBioMed Central | 25 % | 164 | 5.74 | 209 | 4 190 USD |
| Cellular OncologySpringer Nature | 29 % | 113 | 4.41 | 74 | 4 390 USD |
| Discover OncologySpringer Nature | 25 % | 767 | 2.41 | 36 | 1 690 USD |
| Oncology ReportsElsevier BV | 28 % | 223 | 3.05 | 131 | Subscription |
| Cancer Management and ResearchDove Medical Press | 29 % | 363 | 2.19 | 91 | 2 836 USD |
| Molecular Therapy — Nucleic AcidsCell Press | 21 % | 324 | 5.25 | 128 | 3 900 USD |
| Clinical Breast CancerElsevier BV | 30 % | 200 | 2.43 | 97 | Subscription; open access option 3 470 USD |
| Molecular CarcinogenesisWiley | 29 % | 160 | 3.13 | 127 | Subscription; open access option 4 490 USD |
| Cellular and Molecular BiologyCellular and Molecular Biology Association | 29 % | 352 | 2.06 | 41 | Subscription |
| CarcinogenesisOxford University Press | 32 % | 102 | 2.94 | 262 | Subscription; open access option 4 835 USD |
| Environmental and Molecular MutagenesisWiley | 38 % | 62 | 2.46 | 124 | Subscription; open access option 3 750 USD |
| Food and Chemical ToxicologyElsevier BV | 22 % | 685 | 3.09 | 260 | Subscription; open access option 4 670 USD |
| Cancer ScienceWiley | 21 % | 406 | 4.38 | 185 | 2 600 USD |
| Medical Science MonitorInternational Scientific Information Inc. | 24 % | 424 | 2.76 | 100 | Subscription |
| Breast CancerSpringer Science+Business Media | 27 % | 144 | 2.95 | 82 | Subscription; open access option 3 890 USD |
| NeoplasmaAEPress | 34 % | 85 | 2.18 | 56 | Subscription |
| Expert Review of Molecular DiagnosticsTaylor & Francis | 25 % | 103 | 4.64 | 105 | Subscription |
| Molecular Diagnosis & TherapyAdis, Springer Healthcare | 25 % | 64 | 6.47 | 73 | Subscription; open access option 5 090 USD |
| Clinical Cancer ResearchAmerican Association for Cancer Research | 21 % | 1 222 | 2.21 | 418 | Subscription |
| Human CellSpringer Science+Business Media | 28 % | 175 | 2.53 | 55 | Subscription; open access option 2 490 USD |
| Open MedicineDe Gruyter Open | 30 % | 224 | 1.77 | 48 | 2 373 USD |
| OncotargetImpact Journals LLC | 28 % | 177 | 2.22 | 222 | Open access, fee unknown |
| JCO Precision OncologyLippincott Williams & Wilkins | 22 % | 253 | 3.42 | 75 | Subscription |
| Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic AgentsBiolife Sas | 30 % | 381 | 1.30 | 26 | Subscription |
| Acta Biochimica et Biophysica SinicaOxford University Press | 24 % | 218 | 2.90 | 88 | Open access, fee unknown |
| Molecular Cancer ResearchAmerican Association for Cancer Research | 25 % | 145 | 3.20 | 157 | Subscription |
| MutagenesisOxford University Press | 37 % | 32 | 2.71 | 123 | Subscription; open access option 4 170 USD |
| Translational Breast Cancer ResearchAME Publishing Company | 30 % | 38 | 4.09 | 13 | Subscription |
| Mutation Research/Reviews in Mutation ResearchElsevier BV | 32 % | 28 | 4.18 | 158 | Subscription; open access option 4 160 USD |
| Breast Cancer Targets and TherapyDove Medical Press | 33 % | 72 | 2.03 | 54 | 2 320 USD |
| BMC Medical GenomicsBioMed Central | 21 % | 286 | 3.17 | 103 | 3 190 USD |
| American Journal of Cancer Researche-Century Publishing Corporation | 23 % | 152 | 2.85 | 18 | Subscription |
| Translational Cancer ResearchAME Publishing Company | 25 % | 490 | 1.44 | 46 | Open access, fee unknown |
| OncogenesisSpringer Nature | 24 % | 61 | 4.32 | 92 | 4 290 USD |
| Genes & DiseasesElsevier BV | 22 % | 291 | 2.19 | 88 | 2 500 USD |
| Pathology & Oncology ResearchSpringer Science+Business Media | 21 % | 108 | 4.29 | 75 | 2 500 USD |
| The Kaohsiung Journal of Medical SciencesWiley | 27 % | 166 | 1.82 | 62 | 1 200 USD |
| Cancer Genomics & ProteomicsPublisher unknown | 30 % | 64 | 2.08 | 37 | Open access, fee unknown |
| Advances in Cancer Biology - MetastasisElsevier BV | 32 % | 32 | 2.47 | 21 | 2 650 USD |
| BioMed Research InternationalHindawi Publishing Corporation | 21 % | 1 144 | 1.22 | 257 | Subscription; open access option 2 680 USD |
| Genes and EnvironmentBioMed Central | 30 % | 35 | 2.41 | 33 | 2 590 USD |
| Critical Reviews in ToxicologyTaylor & Francis | 20 % | 41 | 7.58 | 186 | Subscription |
| Journal of Breast CancerPublisher unknown | 30 % | 47 | 2.11 | 63 | 500 USD |
| Biomarkers in MedicineFuture Medicine | 22 % | 131 | 2.20 | 71 | Subscription |
| Human GeneElsevier BV | 29 % | 100 | 1.24 | 10 | Subscription; open access option 3 090 USD |
| Breast DiseaseIOS Press | 24 % | 44 | 3.31 | 41 | Subscription |
| Cancer ResearchAmerican Association for Cancer Research | 21 % | 8 237 | 0.61 | 469 | Subscription |
| Journal of Environmental Science and Health Part CTaylor & Francis | 25 % | 16 | 6.02 | 68 | Subscription |
| Journal of Molecular PathologyMultidisciplinary Digital Publishing Institute | 25 % | 31 | 3.13 | 14 | 1 207 USD |
| Disease MarkersHindawi Publishing Corporation | 24 % | 283 | 1.13 | 101 | Subscription; open access option 2 550 USD |
| Cellular Physiology and BiochemistryKarger Publishers | 22 % | 91 | 2.27 | 138 | 1 925 USD |
| Molecular & Cellular ToxicologySpringer Science+Business Media | 24 % | 94 | 1.77 | 35 | Subscription; open access option 3 990 USD |
| Tumor BiologySAGE Publishing | 27 % | 21 | 3.05 | 122 | 2 000 USD |
| Breast CareKarger Publishers | 27 % | 68 | 1.30 | 63 | Subscription |
| Analytical Cellular PathologySpringer Science+Business Media | 26 % | 50 | 1.65 | 62 | 2 160 USD |
| Breast Cancer Basic and Clinical ResearchSAGE Publishing | 26 % | 23 | 2.43 | 46 | 2 650 USD |
| Critical Reviews in Eukaryotic Gene ExpressionBegell House | 26 % | 64 | 1.19 | 79 | Subscription |
| The Breast JournalWiley | 21 % | 66 | 1.69 | 100 | 2 350 USD |
| Experimental OncologyPublisher unknown | 25 % | 63 | 1.16 | 23 | Subscription |
| The International Journal of Biological MarkersSAGE Publishing | 24 % | 33 | 1.82 | 55 | 2 800 USD |
| Current Breast Cancer ReportsSpringer Science+Business Media | 26 % | 45 | 1.23 | 31 | Subscription; open access option 4 090 USD |
| Journal of Cancer Biomoleculars and TherapeuticsPublisher unknown | 35 % | 7 | 2.21 | 5 | Open access, fee unknown |
| International Journal of Breast CancerHindawi Publishing Corporation | 26 % | 19 | 1.79 | 47 | 1 000 USD |
| Biomarker InsightsSAGE Publishing | 22 % | 22 | 2.32 | 52 | 2 650 USD |
| Cancer InformaticsSAGE Publishing | 23 % | 29 | 1.51 | 49 | 2 650 USD |
| OncoscienceImpact Journals LLC | 27 % | 26 | 0.91 | 42 | Open access, fee unknown |
| ExRNABioMed Central | 36 % | 17 | 0.58 | 17 | Open access, fee unknown |
| Precision Medical SciencesWiley | 24 % | 33 | 0.56 | 9 | 2 200 USD |
| Archives of Breast CancerKaviani Breast Disease Institute | 21 % | 59 | 0.53 | 12 | Open access, fee unknown |
| Advances in Breast Cancer ResearchScientific Research Publishing | 23 % | 13 | 0.71 | 15 | Open access, fee unknown |
| Asia-Pacific Journal of OncologyPublisher unknown | 23 % | 8 | 0.42 | 3 | Open access, fee unknown |
| Journal of Breast Cancer ResearchPublisher unknown | 22 % | 8 | 0.24 | 2 | Subscription |
| Breast Global JournalMedknow | 22 % | 11 | 0.04 | 1 | Subscription |
| Cancer Genetics and EpigeneticsPublisher unknown | 25 % | 13 | 0.02 | 2 | Open access, fee unknown |
Which of these fit your paper?
Paste your title and abstract and get these journals ranked for your work, with the closest published articles as evidence. Free, and your abstract is never stored.
Journals in CWTS Journal Indicators Core or the Directory of Open Access Journals that published at least 20 articles in the last five years, mostly in English. "In this field" is the share of a journal's articles that OpenAlex classifies in Cancer Research. Citation rate is OpenAlex's two-year mean citedness, an open measure similar to the journal impact factor. Fees are taken from OpenAlex and DOAJ and can be out of date: always check the journal's own website before you submit.